126 related articles for article (PubMed ID: 1596880)
21. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
23. Targeting and anti-tumor efficacy of liposomal 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma.
Asai T; Shuto S; Matsuda A; Kakiuchi T; Ohba H; Tsukada H; Oku N
Cancer Lett; 2001 Jan; 162(1):49-56. PubMed ID: 11121862
[TBL] [Abstract][Full Text] [Related]
24. Antitumor characteristics of the conjugate of N4-(4-carboxybutyryl)-ara-C with ethylenediamine-introduced dextran and its resistance to cytidine deaminase.
Onishi H; Pithayanukul P; Nagai T
Drug Des Deliv; 1990 Oct; 6(4):273-80. PubMed ID: 1707277
[TBL] [Abstract][Full Text] [Related]
25. Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.
Wallace RE; Lindh D; Durr FE
Cancer Chemother Pharmacol; 1989; 25(2):117-23. PubMed ID: 2480854
[TBL] [Abstract][Full Text] [Related]
26. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Azuma A; Huang P; Matsuda A; Plunkett W
Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616
[TBL] [Abstract][Full Text] [Related]
27. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
Asai T; Shimizu K; Kondo M; Kuromi K; Watanabe K; Ogino K; Taki T; Shuto S; Matsuda A; Oku N
FEBS Lett; 2002 Jun; 520(1-3):167-70. PubMed ID: 12044891
[TBL] [Abstract][Full Text] [Related]
28. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
29. Modulation of the effect of 1-beta-D-arabinofuranosylcytosine based on changes of cytidine deaminase activity in HL60 cells.
Mejer JN; Mortensen BT; Christensen IJ
Med Oncol Tumor Pharmacother; 1990; 7(1):25-9. PubMed ID: 2338846
[TBL] [Abstract][Full Text] [Related]
30. Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids.
Hong CI; Kirisits AJ; Nechaev A; Buchheit DJ; West CR
J Med Chem; 1990 May; 33(5):1380-6. PubMed ID: 2329558
[TBL] [Abstract][Full Text] [Related]
31. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
Chemotherapy; 1989; 35(3):181-6. PubMed ID: 2766858
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo antileukemic effect of novel dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine.
Rauko P; Novotny L; Mego M; Saiko P; Schott H; Szekeres T
Neoplasma; 2007; 54(1):68-74. PubMed ID: 17203895
[TBL] [Abstract][Full Text] [Related]
33. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
Rahman YE; Patel KR; Cerny EA; Maccoss M
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
[TBL] [Abstract][Full Text] [Related]
34. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
Liu X; Jiang Y; Nowak B; Hargis S; Plunkett W
Mol Cancer Ther; 2016 Oct; 15(10):2302-2313. PubMed ID: 27474148
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
Lin TS; Luo MZ; Liu MC; Clarke-Katzenburg RH; Cheng YC; Prusoff WH; Mancini WR; Birnbaum GI; Gabe EJ; Giziewicz J
J Med Chem; 1991 Aug; 34(8):2607-15. PubMed ID: 1652024
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization.
Asai T; Kurohane K; Shuto S; Awano H; Matsuda A; Tsukada H; Namba Y; Okada S; Oku N
Biol Pharm Bull; 1998 Jul; 21(7):766-71. PubMed ID: 9703265
[TBL] [Abstract][Full Text] [Related]
37. [Design of a new antitumor nucleoside CNDAC, against solid tumors].
Matsuda A
Gan To Kagaku Ryoho; 1996 Jan; 23(2):202-10. PubMed ID: 8611048
[TBL] [Abstract][Full Text] [Related]
38. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
Azuma A; Huang P; Matsuda A; Plunkett W
Biochem Pharmacol; 2001 Jun; 61(12):1497-507. PubMed ID: 11377379
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Harrison SD; O'Dwyer PJ; Trader MW
Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
[TBL] [Abstract][Full Text] [Related]
40. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
